Lisa Graham, MD
Ophthalmology · Duluth, MNNPI 1720059603
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $518 of the $637 with a category attached, or 81.4%. It is spread thinly across 14 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.
Across 25 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- The Cameron-ehlen Group, Inc.$113
- AbbVie$111
- Alcon$93
- Rxsight Inc$71
- Carl Zeiss Meditec AG$39
- Tarsus Pharmaceuticals, Inc.$36
- plus $174 from 8 others
Across 3 payments — averaging $6666.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$20K
What the payments were for
- Food & beverage$51881%
- Education$8013%
- Gifts$396%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| The Cameron-ehlen Group, Inc. | 3 | $113 |
| AbbVie(2 entities) | 4 | $111 |
| Alcon | 4 | $93 |
| Rxsight Inc | 3 | $71 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| Glaukos Corporation | 1 | $29 |
| Sight Sciences, Inc. | 1 | $26 |
| Dompe US, Inc. | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $19 |
| Coopervision Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $15 |
How this compares
$637 in reported general payments places this provider in the 60th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 34 | $30,182 |
| Cyclosporine | 37 | $21,658 |
| LumiganBimatoprost | 25 | $16,801 |
| Latanoprost | 574 | $10,131 |
| XiidraLifitegrast | 12 | $9,713 |
| Prednisolone Acetate | 178 | $8,806 |
| Brimonidine Tartrate | 42 | $8,781 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $5,895 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $5,839 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 215 | $4,828 |
| Ketorolac Tromethamine | 144 | $3,547 |
| Timolol Maleate | 204 | $2,579 |
| Ofloxacin | 131 | $1,673 |
| Dorzolamide Hcl | 44 | $773 |
| Doxycycline Monohydrate | 15 | $433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $111 | $52,82378 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 330 ophthalmology providers in Minnesota.
Other ophthalmology in Duluth
- Mostafa MazenDuluth$3K
- Edwin RyanMinneapolis$9.6M
- Mark LobanoffSt Louis Park$6.3M
- Richard LindstromBloomington$5.6M
- Thomas SamuelsonMinnetonka$435K
- Deborah RistvedtAlexandria$392K
- Yun-Sen ChuBloomington$222K
- Sophie BakriRochester$183K
- David HardtenMinneapolis$119K
- John ChenRochester$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.